FDA WARNING_LETTER - HydraMed IV LLC dba HydraMed - March 01, 2026

On June 8, 2026, the FDA issued a Warning Letter to HydraMed IV LLC (dba HydraMed), following a March 2026 review of the company’s website. The agency identified significant violations regarding the promotion of compounded drug products, specifically semaglutide and tirzepatide. The FDA determined that HydraMed’s online representations were false and misleading, resulting in the products being misbranded under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The main violations include labels that incorrectly suggested HydraMed was the actual manufacturer of the drugs and claims that the products were sourced from an "FDA-approved pharmacy." The FDA explicitly stated that it does not grant "FDA-approved" or "FDA-licensed" designations to compounding pharmacies or outsourcing facilities. These misleading claims imply a level of federal authorization and safety review that does not exist for compounded products.

HydraMed is required to submit a written response within 15 business days detailing the corrective actions taken to address these violations and prevent their recurrence. This must include identifying the actual producers of the drug products, providing representative labeling samples, and modifying or removing false claims from their website. Failure to comply may result in legal action, such as product seizures or injunctions.